Table 1

Clinicopathological variables of study population

Discovery set (N=16)Validation set
(N=15)
Sex
 Female5 (31%)4 (27%)
 Male11 (69%)11 (73%)
Age
 ≥669 (56%)7 (47%)
 <667 (44%)8 (53%)
Therapy line
 Second13 (81%)12 (75%)
 Third3 (19%)3 (25%)
First-line TKI
 Sunitinib11 (69%)8 (53%)
 Pazopanib5 (31%)7 (47%)
IMDC score
 Good risk5 (31%)5 (33%)
 Intermediate risk11 (69%)10 (67%)
  • IMDC, International Metastatic RCC Database Consortium; TKI, tyrosine kinase inhibitor .